<a href="https://www.fiercebiotech.com/medtech/foundation-medicine-tallies-fda-nod-pair-its-blood-test-pfizers-prostrate-cancer-combo" hreflang="en">Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo</a>
Foundation Medicine has received FDA approval to use its genomic profiling blood test alongside Pfizer's prostate cancer treatment combination of Talzenna and Xtandi, aimed at identifying patients with specific HRR gene mutations in metastatic castration-resistant prostate cancer. This marks the ninth FDA-approved companion diagnostic for prostate cancer, emphasizing the importance of personalized treatment through comprehensive genomic profiling.
Foundation Medicine's recent FDA approval for its blood test, used in conjunction with Pfizer's prostate cancer combo, highlights the increasing importance of companion diagnostics in precision medicine. This approval emphasizes the need for high-quality genomic profiling to identify patients who can benefit from targeted therapies, presenting a significant opportunity for investment in companies that are expanding capabilities in companion diagnostics and personalized treatment plans.